The COG phase 3 trial AAML1031 (NCT01371981) is currently assessing the efficacy of non-randomized sorafenib addition to chemotherapy and best available donor HSCT for children and AYAs with de novo FLT3–ITD AML. Here, FLT3 is linked to acute myeloid leukemia.